LT2504353T - Lipopeptidų kompozicijos ir susiję būdai - Google Patents

Lipopeptidų kompozicijos ir susiję būdai

Info

Publication number
LT2504353T
LT2504353T LTEP10832379.1T LT10832379T LT2504353T LT 2504353 T LT2504353 T LT 2504353T LT 10832379 T LT10832379 T LT 10832379T LT 2504353 T LT2504353 T LT 2504353T
Authority
LT
Lithuania
Prior art keywords
related methods
lipopeptide compositions
lipopeptide
compositions
methods
Prior art date
Application number
LTEP10832379.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Sophie Sun
Gaauri Naik
Sandra O`CONNOR
Original Assignee
Cubist Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2504353(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals Llc filed Critical Cubist Pharmaceuticals Llc
Publication of LT2504353T publication Critical patent/LT2504353T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP10832379.1T 2009-11-23 2010-11-23 Lipopeptidų kompozicijos ir susiję būdai LT2504353T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23
PCT/US2010/057910 WO2011063419A2 (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Publications (1)

Publication Number Publication Date
LT2504353T true LT2504353T (lt) 2018-09-25

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10832379.1T LT2504353T (lt) 2009-11-23 2010-11-23 Lipopeptidų kompozicijos ir susiję būdai

Country Status (33)

Country Link
US (3) US8835382B2 (enExample)
EP (2) EP3417849A1 (enExample)
JP (3) JP6041673B2 (enExample)
CN (3) CN108785654A (enExample)
AR (2) AR079127A1 (enExample)
AU (1) AU2010321531C1 (enExample)
BR (1) BR112012012406B1 (enExample)
CA (1) CA2781666C (enExample)
CL (2) CL2012001336A1 (enExample)
CO (1) CO6541585A2 (enExample)
CR (1) CR20120271A (enExample)
CY (1) CY1120854T1 (enExample)
DK (1) DK2504353T4 (enExample)
DO (1) DOP2012000140A (enExample)
EC (1) ECSP12011939A (enExample)
ES (1) ES2686331T5 (enExample)
FI (1) FI2504353T4 (enExample)
HR (1) HRP20181380T4 (enExample)
HU (1) HUE039967T2 (enExample)
IL (1) IL219891B (enExample)
LT (1) LT2504353T (enExample)
MX (1) MX2012005993A (enExample)
NZ (1) NZ600118A (enExample)
PE (2) PE20121517A1 (enExample)
PL (1) PL2504353T5 (enExample)
PT (1) PT2504353T (enExample)
RS (1) RS57566B2 (enExample)
RU (1) RU2607526C2 (enExample)
SG (1) SG10201407724YA (enExample)
SI (1) SI2504353T2 (enExample)
TR (1) TR201812823T4 (enExample)
TW (2) TWI606838B (enExample)
WO (1) WO2011063419A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
CN108785654A (zh) 2009-11-23 2018-11-13 丘比斯特制药有限责任公司 脂肽组合物和相关方法
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
RU2013157188A (ru) * 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
EP2802340B1 (en) * 2012-01-12 2020-10-28 Celgene Corporation Romidepsin formulations and uses thereof
DK2887953T3 (en) * 2012-08-23 2018-01-15 Agila Specialties Private Ltd IMPROVED, INJECTABLE DAPTOMYCIN INFORMATION
HUE071031T2 (hu) 2012-09-11 2025-07-28 Hospira Australia Pty Ltd Daptomicinkészítmények és alkalmazásaik
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) * 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
CN114828873A (zh) * 2019-12-26 2022-07-29 尼普洛株式会社 含有达托霉素的稳定的冷冻干燥制剂
CN118873500A (zh) 2020-02-28 2024-11-01 埃克斯利亚制药有限公司 达托霉素制剂
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
DK165416C (da) 1984-10-09 1993-04-05 Lilly Co Eli Fremgangsmaade til fremstilling af derivater af det antibiotisk virksomme cycliske peptid a-21978c
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
EP0386951A3 (en) * 1989-03-06 1992-05-20 Eli Lilly And Company An improved diluent formulation for daptomycin
DK0438813T3 (da) 1990-01-26 1998-07-27 Hoechst Ag Nyt antibiotikum, deoxymulundocandin, en fremgangsmåde til dets fremstilling samt dets anvendelse som lægemiddel
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (enExample) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
CA2133644C (en) 1992-04-20 2008-09-09 Alexander H. T. Chu Process for making vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
SI1115417T1 (sl) 1998-09-25 2006-08-31 Cubist Pharm Inc Uporaba daptomicina
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
CA2394350A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
MXPA02012670A (es) * 2000-06-21 2003-10-06 Cubist Pharm Inc Composiciones y metodos para mejorar la absorcion oral de agentes anti-microbianos.
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
EP1343811A4 (en) * 2000-12-18 2004-12-08 Cubist Pharm Inc METHOD FOR PRODUCING PURIFIED LIPOPEPTIDES
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重t細胞エピトープポリペプチドの酢酸塩組成物
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP2005508622A (ja) 2001-08-06 2005-04-07 キュービスト ファーマシューティカルズ, インコーポレイテッド ダプトマイシン生合成遺伝子クラスターに関する組成物および方法
EP1465930B1 (fr) 2002-01-17 2006-05-03 Arkema Polymeres supramoleculaires
AU2003248921A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−11含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
WO2006085337A1 (en) * 2005-02-14 2006-08-17 Venus Remedies Limited Parenteral combination therpy for infective conditions with drug resistant bacterium
CA2610716A1 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR101536781B1 (ko) 2006-07-26 2015-07-14 산도즈 아게 카스포펀진 제형
EP2084519B1 (en) 2006-10-10 2012-08-01 Los Alamos National Security, LLC X-ray fluorescence analysis method
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
US20100137197A1 (en) 2007-06-26 2010-06-03 Sachin Mittal Lyophilized anti-fungal composition
BRPI0818818A2 (pt) * 2007-10-25 2015-04-22 Novartis Ag Condicionamento de pó
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
US8901072B2 (en) 2009-08-12 2014-12-02 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CN108785654A (zh) 2009-11-23 2018-11-13 丘比斯特制药有限责任公司 脂肽组合物和相关方法
JP2013511522A (ja) 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
PH12013500882A1 (en) 2010-11-01 2020-10-19 Melinta Subsidiary Corp Pharmaceutical compositions
US20120202823A1 (en) 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
EP2670418A4 (en) 2011-02-04 2015-06-17 Aegis Therapeutics Llc ORAL BIO-AVAILABLE PEPTIDARY MATERIAL COMPOSITIONS AND METHOD THEREFOR

Also Published As

Publication number Publication date
HRP20181380T4 (hr) 2023-11-10
EP3417849A1 (en) 2018-12-26
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
TW201703791A (zh) 2017-02-01
RS57566B2 (sr) 2023-12-29
PE20121517A1 (es) 2012-11-26
JP2017075186A (ja) 2017-04-20
ES2686331T5 (es) 2024-03-27
CL2012001336A1 (es) 2012-10-05
RU2607526C2 (ru) 2017-01-10
US8835382B2 (en) 2014-09-16
MX2012005993A (es) 2012-11-23
JP2016147874A (ja) 2016-08-18
NZ600118A (en) 2014-08-29
AR123846A2 (es) 2023-01-18
US20120270772A1 (en) 2012-10-25
PL2504353T5 (pl) 2023-11-20
JP6088681B2 (ja) 2017-03-01
CN102712677A (zh) 2012-10-03
CN104056250A (zh) 2014-09-24
JP6239167B2 (ja) 2017-11-29
CA2781666C (en) 2017-02-21
CY1120854T1 (el) 2019-12-11
US20140364380A1 (en) 2014-12-11
AU2010321531A2 (en) 2014-10-30
CA2781666A1 (en) 2011-05-26
CR20120271A (es) 2012-08-01
AR079127A1 (es) 2011-12-28
RU2012126076A (ru) 2013-12-27
ES2686331T3 (es) 2018-10-17
BR112012012406A2 (pt) 2019-12-03
PL2504353T3 (pl) 2018-11-30
US9138456B2 (en) 2015-09-22
TWI548414B (zh) 2016-09-11
AU2010321531A1 (en) 2012-06-14
BR112012012406B1 (pt) 2021-11-16
SG10201407724YA (en) 2014-12-30
EP2504353A2 (en) 2012-10-03
EP2504353A4 (en) 2014-04-02
AU2010321531B2 (en) 2016-11-03
CO6541585A2 (es) 2012-10-16
SI2504353T2 (sl) 2023-11-30
JP6041673B2 (ja) 2016-12-14
IL219891B (en) 2018-01-31
WO2011063419A2 (en) 2011-05-26
HUE039967T2 (hu) 2019-02-28
US20160030577A1 (en) 2016-02-04
US9662397B2 (en) 2017-05-30
AU2010321531C1 (en) 2020-10-01
CN102712677B (zh) 2015-06-03
PE20151717A1 (es) 2015-11-19
DK2504353T4 (da) 2023-11-20
IL219891A0 (en) 2012-07-31
HRP20181380T1 (hr) 2018-10-19
EP2504353B1 (en) 2018-07-11
SI2504353T1 (sl) 2018-10-30
CL2015002412A1 (es) 2016-02-05
CN108785654A (zh) 2018-11-13
ECSP12011939A (es) 2012-07-31
DOP2012000140A (es) 2012-10-30
EP2504353B2 (en) 2023-09-13
FI2504353T4 (fi) 2023-11-30
JP2013511557A (ja) 2013-04-04
RS57566B1 (sr) 2018-10-31
PT2504353T (pt) 2018-10-18
DK2504353T3 (en) 2018-09-10
TR201812823T4 (tr) 2019-02-21
WO2011063419A3 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
IL219891A0 (en) Lipopeptide compositions and related methods
IL210153A0 (en) Nutrigenomics methods and compositions
EP2483221A4 (en) FERTILIZER COMPOSITIONS AND METHOD THEREFOR
GB201006373D0 (en) Sealing compositions and methods
SI3812360T1 (sl) Monoklorotrifluoropropenske spojine in sestavki ter postopki, ki jih uporabljajo
PH12013500698A1 (en) Hair-mending compositions and associated methods
SG10201701954QA (en) Anti-cxcr1 compositions and methods
IL218212A0 (en) Therapeutic methods and compositions
GB0819530D0 (en) Methods and compositions
GB0903299D0 (en) Composition and methods
EP2512483A4 (en) BALAGLITAZON COMPOSITIONS AND METHOD THEREFOR
GB201018650D0 (en) Methods and compositions
EP2490536A4 (en) COMPOSITION AND METHOD
GB0902429D0 (en) Compositions and their use
GB0901494D0 (en) Compositions and Methods
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
GB0811250D0 (en) Methods and compositions
EP2488624A4 (en) STABILIZED SURFACTANT-OXIDANT COMPOSITIONS AND METHODS THEREOF
GB0907616D0 (en) Methods and compositions
GB0908498D0 (en) Compositions and methods
GB0903913D0 (en) Compositions and methods
GB0909720D0 (en) Compositions and methods
GB0901899D0 (en) Compositions and uses
GB201018651D0 (en) Methods and compositions